626 related articles for article (PubMed ID: 14728084)
1. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Stahl SM; Shayegan DK
J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
[TBL] [Abstract][Full Text] [Related]
2. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of ziprasidone: an expanding perspective.
Daniel DG
J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
[TBL] [Abstract][Full Text] [Related]
4. Maintaining symptom control: review of ziprasidone long-term efficacy data.
Schooler NR
J Clin Psychiatry; 2003; 64 Suppl 19():26-32. PubMed ID: 14728087
[TBL] [Abstract][Full Text] [Related]
5. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
6. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():19-25. PubMed ID: 14728086
[TBL] [Abstract][Full Text] [Related]
7. Focus on ziprasidone.
Green B
Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
[TBL] [Abstract][Full Text] [Related]
8. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
9. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
10. Receptor mechanisms in the treatment of schizophrenia.
Reynolds GP
J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone and cognition: the evolving story.
Harvey PD
J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
[TBL] [Abstract][Full Text] [Related]
12. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
[No Abstract] [Full Text] [Related]
13. Using oral ziprasidone effectively: the food effect and dose-response.
Citrome L
Adv Ther; 2009 Aug; 26(8):739-48. PubMed ID: 19669631
[TBL] [Abstract][Full Text] [Related]
14. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
Keegan D
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S46-52. PubMed ID: 7533051
[TBL] [Abstract][Full Text] [Related]
15. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
[TBL] [Abstract][Full Text] [Related]
16. From clinical research to clinical practice: a 4-year review of ziprasidone.
Nemeroff CB; Lieberman JA; Weiden PJ; Harvey PD; Newcomer JW; Schatzberg AF; Kilts CD; Daniel DG
CNS Spectr; 2005 Nov; 10(11 Suppl 17):1-20. PubMed ID: 16381088
[TBL] [Abstract][Full Text] [Related]
17. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
18. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; CarriĆ³ I; Alvarez E
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
[TBL] [Abstract][Full Text] [Related]
19. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
Kuroki T; Nagao N; Nakahara T
Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
[TBL] [Abstract][Full Text] [Related]
20. Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic.
Daniel DG; Copeland LF
Expert Opin Investig Drugs; 2000 Apr; 9(4):819-28. PubMed ID: 11060712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]